Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Recently, a number of Chinese listed IVD companies released 2020 annual performance report, disclosing their revenue. Driven by the demand of testing products of COVID-19, the performance growth is very gratifying.

On the evening of February 19, FTSE Russell, an international index compilation company, announced the quarterly review results of its flagship index, adding 129 A-share targets in total. Edan Instruments (300206. SZ) officially entered the

As of February 20, 2021, FDA has urgently authorized 14 COVID-19 antigen tests, involving 11 companies: Abbott、Ortho、Quidel 、BD、LumiraDx、Access Bio、Princeton BioMeditech、Luminostics、Celltrion、Quanterix、Ellume.

Recently， there are many IVD companies that complete the financing, including Ustar, GENFINE BIOTECH, Accunome, Legendaibiochip and Vision Medicals.

On February 18, 2021, New Horizon Health was officially listed on HK stock exchange.

Find out what is going on in Chinese in vitro diagnostic industry

SARS-CoV-2 Inactivated Vaccine (Vero cells) developed by Beijing Sinovac Biotech Co., Ltd was approved for marketing with conditions.

In order to promote the improvement of the technology and ensure the quality of medical laboratory testing, Shanghai Clinical Laboratory Center invited 10 hospitals to participate in the multi institute performance evaluation and validation

Sansure Biotech enters the pet market, pet medical is expected to become the company's new growth pole.

On January 30, 2021, Amoy Diagnostics and AstraZeneca signed a strategic cooperation on HRD testing and companion diagnosis for ovarian cancer.